Shilpa Medicare’s marketing partner, Amneal Pharmaceuticals, has launched BORUZU™ (Bortezomib for Injection, 3.5mg/1.4ml) in the U.S. market. This ready-to-use oncology product is designed for subcutaneous or intravenous (IV) administration, reducing preparation steps for healthcare providers. The product has already received a permanent J-code from the U.S. Centers for Medicare & Medicaid Services (CMS), ensuring streamlined reimbursement.
BORUZU™, a proteasome inhibitor, is used to treat multiple myeloma and mantle cell lymphoma. Unlike Velcade®, the reference drug that requires reconstitution, BORUZU™ is a ready-to-use solution, enhancing efficiency and reducing patient wait times.
Shilpa Medicare developed the molecule, while Amneal Pharmaceuticals will handle manufacturing and commercialization in the U.S. market.
Vishnukant Bhutada, Managing Director of Shilpa Medicare, emphasized the company’s commitment to pharmaceutical innovation, stating, “This is the second NDA product being launched in the US market from our novel injectable portfolio demonstrates our capabilities and commitment to introduce pharmacy efficient solutions that enhance compliance and have the potential to reduce patient wait times. This development exemplifies Shilpa’s constant endeavor to work towards introducing novel first of its kind pharmaceutical products that help improve the healthcare requirements of a large patient pool.”
